Abstract
Abstract Although Hodgkin lymphoma has become one of the most curable lymphomas, 20-30% of patients still relapse after first-line treatment. In relapsed patients, high dose chemotherapy followed by autologous stem cell transplantation (HDC/ASCT) is a standard treatment approach, however transplant-ineligible patients or patients who relapse after HDC/ASCT still have a rather poor prognosis. Immuno-checkpoint inhibitors are one of the most promising cancer immunotherapies in various advanced cancers including hematologic malignancies. PD-1-blocking antibodies have been used to enhance immunity in several malignancies and obtain durable responses, especially in the patients with heavily treated relapsed/refractory Hodgkin lymphoma. Nowadays, several clinical trials including single agent or combination therapies for Hodgkin lymphoma have been developed or are currently under investigation. The results of ongoing and future clinical trials may establish new treatment paradigm in Hodgkin lymphoma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
